A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs GRI 0621 (Primary)
- Indications Hepatitis B; Hepatitis C; Liver disorders; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms GRI-201
- Sponsors GRI Bio
- 16 Feb 2018 Last checked against ClinicalTrials.gov record.
- 13 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 13 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.